MedPath

DECAMP-1: Diagnosis and Surveillance of Indeterminate Pulmonary Nodules

Completed
Conditions
Lung Cancer
Interventions
Other: Biosample and Imaging Collection
Registration Number
NCT01785342
Lead Sponsor
Boston University
Brief Summary

The goal is to improve the efficiency of the diagnostic follow-up of patients with indeterminate pulmonary nodules by determining whether biomarkers for lung cancer diagnosis that are measured in minimally invasive biospecimens are able to distinguish malignant from benign pulmonary nodules that are incidentally detected in high-risk smokers.

Detailed Description

The Detection of Early lung Cancer Among Military Personnel (DECAMP) consortium is a multidisciplinary and translational research program that includes 7 Veterans Administration Hospitals (VAH), the 4 designated Military Treatment Facilities (MTF) and 4 academic hospitals as clinical study sites, several molecular biomarker laboratories, along with Biostatics, Bioinformatics, Pathology and Biorepository cores. The DECAMP Coordinating Center will facilitate rapid selection, design and execution of clinical studies within this multi-institutional consortium. The goal will be accomplished by recruiting 500 smokers with indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic bronchoscopy and will be followed for 2 years until a final diagnosis is made. The diagnostic performance of four previously established lung cancer biomarkers in this cohort will be validated; 1) a gene-expression biomarker measured in bronchial airway brushings; 2) a proteomic signatures measured in bronchial airway biopsies; 3) a proteomic signature measured in serum; and 4) a signature of serum cytokines. The added value of the molecular markers to clinical and imaging markers routinely used in the diagnostic work up of these patients and develop an integrated model (i.e. clinical, imaging \& molecular markers) that results in the most robust diagnostic predictor will be evaluated.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
489
Inclusion Criteria
  • 45 years of age or older;
  • Initial diagnosis of indeterminate pulmonary nodule (0.7-3.0 cm);
  • Smoking status: Current or former smoker with โ‰ฅ 20 pack years (pack years = number of packs per day X number of years smoked)
  • Willing to undergo fiberoptic bronchoscopy;
  • Able to tolerate all biospecimen collection as required by protocol;
  • Able to comply with standard of care follow up visits including clinical exams, diagnostic work-ups, and imaging for a minimum of two years;
  • Able to fill out Patient Lung History questionnaire;
  • Willing and able to provide a written informed consent.
Exclusion Criteria
  • History or previous diagnosis of lung cancer;
  • Diagnosis of pure ground glass opacities on chest CT;
  • Contraindications to nasal brushing or fiberoptic bronchoscopy including ulcerative nasal disease, hemodynamic instability, severe obstructive airway disease, unstable cardiac or pulmonary disease; inability to protect airway or altered level of consciousness;
  • Allergies to any local anesthetic that may be used to obtain biosamples in the study.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Indeterminate Pulmonary NoduleBiosample and Imaging CollectionThe goal will be accomplished by recruiting 500 smokers with indeterminate pulmonary nodules (0.7cm - 3.0cm) on chest CT who will undergo fiberoptic bronchoscopy and will be followed for 2 years until a final diagnosis is made. Biosample and imaging collection will be done.
Primary Outcome Measures
NameTimeMethod
Lung Cancer2 years

Subjects will be identified as Lung Cancer or no Lung Cancer (through diagnosis) within the 2 year followup period.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (15)

Walter Reed National Military Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Bethesda, Maryland, United States

Health Research Inc. Roswell Park Division

๐Ÿ‡บ๐Ÿ‡ธ

Buffalo, New York, United States

Regents of the University of California LA (Los Angeles VA Healthcare System)

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Trustees of University of Pennsylvania (Philadelphia VA Medical Center)

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

University of California Los Angeles Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Los Angeles, California, United States

Naval Medical Center San Diego

๐Ÿ‡บ๐Ÿ‡ธ

San Diego, California, United States

Naval Medical Center Portsmouth

๐Ÿ‡บ๐Ÿ‡ธ

Portsmouth, Virginia, United States

Denver Research Institute

๐Ÿ‡บ๐Ÿ‡ธ

Denver, Colorado, United States

Boston University Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Middle Tennessee Research Institute (Vanderbilt University)

๐Ÿ‡บ๐Ÿ‡ธ

Nashville, Tennessee, United States

San Antonio Military Medical Center

๐Ÿ‡บ๐Ÿ‡ธ

San Antonio, Texas, United States

Boston VA Research Institute, Inc

๐Ÿ‡บ๐Ÿ‡ธ

Boston, Massachusetts, United States

Veterans Research Foundation of Pittsburgh

๐Ÿ‡บ๐Ÿ‡ธ

Pittsburgh, Pennsylvania, United States

University of Pennsylvania

๐Ÿ‡บ๐Ÿ‡ธ

Philadelphia, Pennsylvania, United States

Dallas VA Research Corporation

๐Ÿ‡บ๐Ÿ‡ธ

Dallas, Texas, United States

ยฉ Copyright 2025. All Rights Reserved by MedPath